← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV17행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
Autologous CD4 T-Cells (Autologous CD4 T-Cells)
University of Pennsylvania·Hiv
31 trials
Overview
Program
Autologous CD4 T-Cells
Overview
Company
University of Pennsylvania
Overview
Modality
CGT
Overview
Target
Hiv
Overview
Indication
Hiv
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Butyrate enhances CD56 bright NK cell-driven killing of activated T cells and modulates NK cell chromatin accessibility.. Gut bacteria-derived metabolites, such as butyrate (BUT), induce T regulatory cells through inhibition of histone deacetylases (HDAC). Natural killer (NK) cells are innate lymphocytes with important effector and regulatory functions; little is known on the effect of BUT on NK c…
Toxicology
CRS
Reported
Clinical
Safety signal
Butyrate enhances CD56 bright NK cell-driven killing of activated T cells and modulates NK cell chromatin accessibility.. Gut bacteria-derived metabolites, such as butyrate (BUT), induce T regulatory cells through inhibition of histone deacetylases (HDAC). Natural killer (NK) cells are innate lymphocytes with important effector and regulatory functions; little is known on the effect of BUT on NK c…
Clinical
Result source
ClinicalTrials.gov NCT02706405
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT02706405